← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Acetic acid derivatives and related substances
etodolac
M01AB08
Forms & Strengths
- Capsules: 200 mg, 300 mg
- Tablets: 400 mg, 500 mg
- Extended-release tablets: 400 mg, 500 mg, 600 mg
Adult Dosing
- Osteoarthritis: 300 mg to 400 mg PO BID or TID (Max: 1200 mg/day); ER formulation 400 mg to 1000 mg PO once daily
- Rheumatoid arthritis: 300 mg to 400 mg PO BID or TID (Max: 1200 mg/day)
- Acute pain: 200 mg to 400 mg PO every 6 to 8 hours as needed (Max: 1000 mg/day)
Pediatric Dosing
- Safety and efficacy have not been established in pediatric patients under 18 years of age
Indications
- Management of the signs and symptoms of osteoarthritis
- Management of the signs and symptoms of rheumatoid arthritis
- Management of acute pain
Mechanism of Action
- Nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis
- Acts primarily by inhibiting cyclooxygenase (COX-2) with some selectivity over COX-1 at lower doses
- Reduces inflammatory mediator production, leading to analgesic, anti-inflammatory, and antipyretic effects
Contraindications
- Known hypersensitivity to etodolac or other NSAIDs
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery
- Active peptic ulcer disease or history of recurrent gastrointestinal bleeding
Adverse Reactions
- Gastrointestinal: dyspepsia, nausea, abdominal pain, diarrhea, constipation, ulceration, bleeding
- Central nervous system: headache, dizziness, drowsiness, insomnia
- Cardiovascular: edema, hypertension, myocardial infarction, stroke
- Renal: elevated serum creatinine, renal impairment, fluid retention
- Hepatic: elevated transaminases
Drug Interactions
- Anticoagulants (e.g., warfarin): increased risk of bleeding
- Antiplatelet agents (e.g., aspirin): increased risk of GI ulceration and bleeding
- ACE inhibitors, ARBs, and diuretics: reduced antihypertensive efficacy and increased risk of renal impairment
- Lithium: decreased renal clearance resulting in elevated lithium toxicity risk
- Methotrexate: increased hematologic toxicity due to reduced clearance
Curated Content: Needs Vetting Before Put to Clinical Use